{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:11:38Z","timestamp":1787897498517,"version":"build-2784847793"},"reference-count":57,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"TB Alliance","award":["LSHTM\/GATB 16003"],"award-info":[{"award-number":["LSHTM\/GATB 16003"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,11,8]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Patients with highly resistant tuberculosis have few treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introducing BPaL against the extensively drug-resistant tuberculosis (XDR-TB) standard of care in three epidemiological settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Cost-effectiveness analysis using Markov cohort model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>South Africa, Georgia and the Philippines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>XDR-TB and multidrug-resistant tuberculosis (MDR-TB) failure and treatment intolerant patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>BPaL regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Primary and secondary outcome measures<\/jats:title>\n                  <jats:p>(1) Incremental cost per disability-adjusted life years averted by using BPaL against standard of care at the Global Drug Facility list price. (2) The potential maximum price at which the BPaL regimen could become cost neutral.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>BPaL for XDR-TB is likely to be cost saving in all study settings when pretomanid is priced at the Global Drug Facility list price. The magnitude of these savings depends on the prevalence of XDR-TB in the country and can amount, over 5 years, to approximately US$ 3 million in South Africa, US$ 200 000 and US$ 60 000 in Georgia and the Philippines, respectively. In South Africa, related future costs of antiretroviral treatment (ART) due to survival of more patients following treatment with BPaL reduced the magnitude of expected savings to approximately US$ 1 million. Overall, when BPaL is introduced to a wider population, including MDR-TB treatment failure and treatment intolerant, we observe increased savings and clinical benefits. The potential threshold price at which the probability of the introduction of BPaL becoming cost neutral begins to increase is higher in Georgia and the Philippines (US$ 3650 and US$ 3800, respectively) compared with South Africa (US$ 500) including ART costs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results estimate that BPaL can be a cost-saving addition to the local TB programmes in varied programmatic settings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-051521","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T11:57:47Z","timestamp":1638532667000},"page":"e051521","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02333799","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03086486","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7409-798X","authenticated-orcid":false,"given":"Gabriela Beatriz","family":"Gomez","sequence":"first","affiliation":[{"name":"Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK"},{"name":"Modelling, Epidemiology and Data Science Department, Sanofi Pasteur, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Siapka","sequence":"additional","affiliation":[{"name":"Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK"},{"name":"Impact Epilysis, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Conradie","sequence":"additional","affiliation":[{"name":"Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6200-1592","authenticated-orcid":false,"given":"Norbert","family":"Ndjeka","sequence":"additional","affiliation":[{"name":"National TB Programme, South Africa Department of Health, Pretoria, Gauteng, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marie Celina","family":"Garfin","sequence":"additional","affiliation":[{"name":"National Tuberculosis Control Program, Bureau of Disease Prevention and Control, Department of Health, Manila, The Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Lomtadze","sequence":"additional","affiliation":[{"name":"Department of TB Surveillance and Strategic Planning, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Avaliani","sequence":"additional","affiliation":[{"name":"Department of TB Surveillance and Strategic Planning, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kiria","sequence":"additional","affiliation":[{"name":"Department of TB Surveillance and Strategic Planning, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Malhotra","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"},{"name":"Global Access, International AIDS Vaccine Initiative (IAVI), New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cook-Scalise","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"},{"name":"TB Division, USAID, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Juneja","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Everitt","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Spigelman","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vassall","sequence":"additional","affiliation":[{"name":"Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"2025101811222237000_11.12.e051521.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31644-1"},{"key":"2025101811222237000_11.12.e051521.2","unstructured":"Global Health Costing Consortium . Unit Cost Study Repository [Internet]. Available: https:\/\/ghcosting.org\/pages\/data\/ucsr\/app\/ [Accessed 05 Jun 2020]."},{"key":"2025101811222237000_11.12.e051521.3","unstructured":"World Health Organization . Global tuberculosis report 2019. Geneva: World Health Organization, 2019."},{"key":"2025101811222237000_11.12.e051521.4","unstructured":"Maddipatla M . U.S. FDA approves TB Alliance\u2019s treatment for drug-resistant tuberculosis. Reuters [Internet], 2019. Available: https:\/\/www.reuters.com\/article\/us-tb-alliance-fda\/u-s-fda-approves-tb-alliances-treatment-for-drug-resistant-tuberculosis-idUSKCN1V41UU [Accessed 05 Jun 2020]."},{"key":"2025101811222237000_11.12.e051521.5","unstructured":"European Medicines Agency . Pretomanid FGK [Internet]. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pretomanid-fgk [Accessed 18 Jan 2021]."},{"key":"2025101811222237000_11.12.e051521.6","unstructured":"Reuters . Mylan gets Indian regulatory approval for tuberculosis drug [Internet]. Available: https:\/\/www.reuters.com\/article\/us-mylan-tuberculosis-india\/mylan-gets-indian-regulatory-approval-for-tuberculosis-drug-idUSKCN24N19K [Accessed 18 Jan 2021]."},{"key":"2025101811222237000_11.12.e051521.7","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment [Internet]. Geneva, 2020. Available: https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1280998\/retrieve"},{"key":"2025101811222237000_11.12.e051521.8","unstructured":"TB Alliance . Our pipeline: BPaL [Internet]. Available: https:\/\/www.tballiance.org\/portfolio\/regimen\/bpal [Accessed 05 Jun 2020]."},{"key":"2025101811222237000_11.12.e051521.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2025101811222237000_11.12.e051521.10","unstructured":"Conradie F , Diacon AH , Ngubane N . Final results of teh NIX-TB clinical study of BPaL regimen for highly resistant TB. virtual, 2021. Available: https:\/\/www.croiconference.org\/abstract\/final-results-of-the-nix-tb-clinical-study-of-bpal-regimen-for-highly-resistant-tb\/"},{"key":"2025101811222237000_11.12.e051521.11","unstructured":"TB Alliance . Our pipeline: ZeNix trial [Internet]. Available: https:\/\/www.tballiance.org\/portfolio\/trial\/11883 [Accessed 18 Jan 2021]."},{"key":"2025101811222237000_11.12.e051521.12","unstructured":"Conradie F . High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid. Berlin, Germany, 2021."},{"key":"2025101811222237000_11.12.e051521.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00811-2015"},{"key":"2025101811222237000_11.12.e051521.14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120763"},{"key":"2025101811222237000_11.12.e051521.15","doi-asserted-by":"crossref","first-page":"A674","DOI":"10.1016\/j.jval.2014.08.2503","article-title":"Costs and effectiveness of combination therapy with bedaquiline and other anti-tuberculosis drugs in patients with multi- and extensively drug-resistant tuberculosis in Germany","volume":"17","author":"Wolfson","year":"2014","journal-title":"Value Health"},{"key":"2025101811222237000_11.12.e051521.16","doi-asserted-by":"crossref","first-page":"A595","DOI":"10.1016\/j.jval.2014.08.2051","article-title":"Cost effectiveness of bedaquiline for the treatment of multidrug-resistant tuberculosis","volume":"17","author":"Wolfson","year":"2014","journal-title":"Value Health"},{"key":"2025101811222237000_11.12.e051521.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-016-1931-3","article-title":"Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries","volume":"17","author":"Lu","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"2025101811222237000_11.12.e051521.18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40258-017-0352-8","article-title":"Incremental cost effectiveness of bedaquiline for the treatment of rifampicin-resistant tuberculosis in South Africa: model-based analysis","volume":"16","author":"Schnippel","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"key":"2025101811222237000_11.12.e051521.19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.5588\/ijtld.17.0869","article-title":"Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis","volume":"22","author":"Schnippel","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025101811222237000_11.12.e051521.20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14737167.2018.1507821","article-title":"Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis","volume":"18","author":"Ionescu","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025101811222237000_11.12.e051521.21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijid.2018.10.007","article-title":"Cost-Effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China","volume":"78","author":"Fan","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2025101811222237000_11.12.e051521.22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/14787210.2020.1742109","article-title":"The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa","volume":"18","author":"Mpobela Agnarson","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025101811222237000_11.12.e051521.23","article-title":"Experience of treatment Pre-XDR and XDR-TB\/HIV co-infection with bedaquiline and delamanid containing regimens in Georgia","volume":"52","author":"Kiria","year":"2018","journal-title":"Eur Respir J"},{"key":"2025101811222237000_11.12.e051521.24","article-title":"Steps of bedaquline implementation in Georgia","volume":"48","author":"Kiria","year":"2016","journal-title":"Eur Respir J"},{"key":"2025101811222237000_11.12.e051521.25","unstructured":"Lofranco V . Introduction of bedaquiline in the Philippines. Manila: Crowne Plaza Hotel, 2017."},{"key":"2025101811222237000_11.12.e051521.26","unstructured":"Philippine Coalition Against Tuberculosis (PhilCAT), Philippine Society for Microbiology and Infectious Diseases (PSMID), Philippine College of Chest Physicians (PCCP) . Task force: clinical practice guidelines for the diagnosis, treatment, prevention and control of tuberculosis in adult Filipinos. Manila, 2016."},{"key":"2025101811222237000_11.12.e051521.27","unstructured":"Republic of South Africa, Department of Health . Interim clinical guidance for the implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adutls, adolescents and children [Internet], 2018. Available: http:\/\/www.tbonline.info\/media\/uploads\/documents\/dr_tb_clinical_guidelines_for_rsa_september_2018.pdf"},{"key":"2025101811222237000_11.12.e051521.28","unstructured":"Georgia Country Coordinating Mechanism . National Strategy for Tuberculosis Control in Georgia 2019-2022 [Internet]. Tbilisi, 2019. Available: http:\/\/www.georgia-ccm.ge\/wp-content\/uploads\/National-Strategy-for-Tuberculosis-Control-in-Georgia-2019-2022.pdf"},{"key":"2025101811222237000_11.12.e051521.29","unstructured":"TB Alliance . Highights of prescribing information [Internet]. New York, 2019. Available: https:\/\/www.tballiance.org\/sites\/default\/files\/assets\/Pretomanid_Full%20Prescribing%20Information.pdf"},{"key":"2025101811222237000_11.12.e051521.30","unstructured":"World Health Organization . WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, 2019."},{"key":"2025101811222237000_11.12.e051521.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.015"},{"key":"2025101811222237000_11.12.e051521.32","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/16.3.326"},{"key":"2025101811222237000_11.12.e051521.33","unstructured":"Global Burden of Disease Collaborative Network . Global burden of disease study 2017 (GBD 2017) disability weights. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2018."},{"key":"2025101811222237000_11.12.e051521.34","unstructured":"Global Health Costing Consortium . Unit Cost Study Repository (UCSR) [Internet], 2018. Available: https:\/\/ghcosting.org\/pages\/data\/ucsr\/app\/ [Accessed 13 Jun 2020]."},{"key":"2025101811222237000_11.12.e051521.35","unstructured":"Sweeney S , Cunnama L , Laurence YV . Value TB Dataset: costs per intervention [Internet]. Harv. Dataverse 2021."},{"key":"2025101811222237000_11.12.e051521.36","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/17.1.112"},{"key":"2025101811222237000_11.12.e051521.37","unstructured":"Stop TB Partnership . The Stop TB Partnership\u2019s Global Drug Facility catalog now lists the first-ever, all-oral regimen for highly resistant forms of drug-resistant tuberculosis at US $1,040 per treatment course [Internet], 2019. Available: http:\/\/www.stoptb.org\/news\/stories\/2019\/ns19_025.html [Accessed 18 Jan 2021]."},{"key":"2025101811222237000_11.12.e051521.38","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5588\/ijtld.19.0409","article-title":"Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis","volume":"24","author":"Masuku","year":"2020","journal-title":"int j tuberc lung dis"},{"key":"2025101811222237000_11.12.e051521.39","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0279-6"},{"key":"2025101811222237000_11.12.e051521.40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025101811222237000_11.12.e051521.41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036599"},{"key":"2025101811222237000_11.12.e051521.42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042390","article-title":"Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the stream trial","volume":"10","author":"Rosu","year":"2020","journal-title":"BMJ Open"},{"key":"2025101811222237000_11.12.e051521.43","unstructured":"Medecins Sans Frontieress . Drug-resistant TB clinical trial ends enrolment early after positive initial data [Internet]. MSF Press Release. Available: https:\/\/www.msf.org\/drug-resistant-tuberculosis-trial-ends-enrolment-after-positive-initial-data [Accessed 20 Aug 2021]."},{"key":"2025101811222237000_11.12.e051521.44","unstructured":"World Health Organization . Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva, 2019."},{"key":"2025101811222237000_11.12.e051521.45","doi-asserted-by":"crossref","first-page":"766","DOI":"10.5588\/ijtld.17.0840","article-title":"Is 6 months of bedaquiline enough? results from the compassionate use of bedaquiline in Armenia and Georgia","volume":"22","author":"Hewison","year":"2018","journal-title":"int j tuberc lung dis"},{"key":"2025101811222237000_11.12.e051521.46","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21498"},{"key":"2025101811222237000_11.12.e051521.47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01528-2018"},{"key":"2025101811222237000_11.12.e051521.48","unstructured":"Department of Health . REVIEW REPORT: 2019 Philippines TB Joint Program Review [Internet], 2019. Available: http:\/\/www.ntp.doh.gov.ph\/downloads\/publications\/assessment_reports\/JPR_2019.pdf"},{"key":"2025101811222237000_11.12.e051521.49","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu186"},{"key":"2025101811222237000_11.12.e051521.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62675-6"},{"key":"2025101811222237000_11.12.e051521.51","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0421"},{"key":"2025101811222237000_11.12.e051521.52","unstructured":"Republic of South Africa, Department of Health . Annexure A1 Upfs2018 Tariffs 01 April 2018 Full Paying [Internet], 2018. Available: http:\/\/www.health.gov.za\/index.php\/shortcodes\/2015-03-29-10-42-47\/2015-04-30-09-10-23\/uniform-patient-fee-schedule\/category\/448-upfs-2018"},{"key":"2025101811222237000_11.12.e051521.53","unstructured":"Republic of South Africa, Department of Health . Master Procurement Catalogue [Internet], 2018. Available: http:\/\/www.health.gov.za\/index.php\/component\/phocadownload\/category\/196"},{"key":"2025101811222237000_11.12.e051521.54","unstructured":"South African National Blood Service . State Patients Pricelist [Internet]., 2019. Available: https:\/\/sanbs.org.za\/product-price-list\/"},{"key":"2025101811222237000_11.12.e051521.55","unstructured":"Stop TB Partnership . GDF Product catalogue [Internet], 2018. Available: http:\/\/www.stoptb.org\/gdf\/drugsupply\/catalogue.asp"},{"key":"2025101811222237000_11.12.e051521.56","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/j.jpainsymman.2017.04.024","article-title":"Palliative care in South Africa","volume":"55","author":"Drenth","year":"2018","journal-title":"J Pain Symptom Manage"},{"key":"2025101811222237000_11.12.e051521.57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210497"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-051521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:22:31Z","timestamp":1760811751000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-051521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":57,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,3]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/bmjopen-2021-051521"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-051521","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}